Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
MK-4830 in Squamous Cell Carcinoma of Head and Neck: NCT06413095 Clinical Landscape Report 2026
16 October 2026
NCT06413095 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Tebentafusp in Uveal Melanoma: NCT06414590 Clinical Landscape Report 2026
16 October 2026
NCT06414590 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BTX-A51 in Liposarcoma: NCT06414434 Clinical Landscape Report 2026
16 October 2026
NCT06414434 clinical landscape for Liposarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 CAR-T Cells(SongGe Biotechnology) in Myositis: NCT06420154 Clinical Landscape Report 2026
16 October 2026
NCT06420154 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ADX 097 in C3 glomerulopathy: NCT06419205 Clinical Landscape Report 2026
16 October 2026
NCT06419205 clinical landscape for C3 glomerulopathy: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 CAR-NK cells(Second Affiliated Hospital, School of Medicine, Zhejiang University) in Systemic Lupus Erythematosus: NCT06421701 Clinical Landscape Report 2026
16 October 2026
NCT06421701 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Malignant Fibrous Histiocytoma: NCT06422806 Clinical Landscape Report 2026
16 October 2026
NCT06422806 clinical landscape for Malignant Fibrous Histiocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/BCMA-CAR-T cells(Essen Biotech) in Sjogren's Syndrome: NCT06428188 Clinical Landscape Report 2026
16 October 2026
NCT06428188 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MVR-T3011 in Non-Muscle Invasive Bladder Neoplasms: NCT06427291 Clinical Landscape Report 2026
16 October 2026
NCT06427291 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Axitinib in Mucosal Melanoma: NCT06424626 Clinical Landscape Report 2026
16 October 2026
NCT06424626 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GIM-531 in Melanoma, Cutaneous Malignant: NCT06425926 Clinical Landscape Report 2026
16 October 2026
NCT06425926 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ATA-3219 in Lupus Nephritis: NCT06429800 Clinical Landscape Report 2026
16 October 2026
NCT06429800 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.